|Day Low/High||2.20 / 2.39|
|52 Wk Low/High||1.92 / 5.47|
We added to one name during a stellar week for the majority of the portfolio.
The Plymouth Meeting, Pa.-based firm said a Phase 1 study of Zika vaccine GLS-5700 'induced high levels of binding antibodies in 100% of participants.'
Phase 1 results show GLS-5700 induced high levels of antibodies in 100% of participants; Serum from vaccinated subjects prevented infection in virus challenge in animals
We took a healthy profit trimming one name and added to three other positions last week.
We added a digital security name to the Bullpen during a mixed week for the portfolio.
Inovio's DNA-based Monoclonal Antibody Programs Boosted by Scientific Publications
Investors in Inovio Pharmaceuticals Inc. saw new options become available this week, for the May 2018 expiration.
We initiated 2 new positions and jettisoned another over the last week.
Korean trial is fully funded by partners and will evaluate Inovio's advanced intradermal delivery system
We remain cautious during this historically volatile month for the market.
INO-5150 generated antigen specific T cell immune responses in a phase 1b clinical study
We scaled into one position during a week dominated by Hurricane Harvey and its aftermath.
We initiated 2 small positions last week as the market moved higher.
Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the October 20th expiration.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
I will leave both INO and PXLW short of what I consider to be full positions.
Energy Recovery has been going wrong all year; but it has potential.
North Korea puts a worrying wrinkle in the markets. We add to 2 portfolio positions.
Expenses rose, revenue was bloated by a deferred lump sum and cash and equivalents has declined.
The most recent short interest data has been released for the 07/31/2017 settlement date, which shows a 2,217,694 share decrease in total short interest for Inovio Pharmaceuticals Inc. , to 8,603,835, a decrease of 20.49% since 07/14/2017.
Five portfolio names report today. Here is what we have seen, and what two expect after the closing bell.
What are the chances of a Draghi dovish surprise? I wouldn't bet the farm on anything.
Jim Cramer says investors should step away from these near-term shenanigans and focus on the fundamentals.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.